Category Archives: Mesenchymal Stem Cells

ExpertBeacon - Nathan Wei - Mesenchymal stem cells can help you in the treatment of osteoarthritis Learn more at http://expertbeacon.com/mesenchymal-stem-cells-can-help-you-treatment-osteoarthritis/ In this video, Nathan Wei explains how mesenchymal stem c... By: ExpertBeacon … Continue reading →

SAN DIEGO, Calif., Aug. 6, 2013 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today announced that it has entered into an agreement with Orbsen Therapeutics Ltd and the National University of Ireland, Galway, to utilize Cardium's Excellagen pharmaceutically-formulated gel as a delivery agent for Orbsen's proprietary stromal cell therapy in pre-clinical studies for the potential treatment of diabetic foot ulcers. The research is being conducted by the Regenerative Medicine Institute (REMEDI), at the National University of Ireland Galway (NUIG), a world-class biomedical research centre focused on mesenchymal stromal cell (MSC) research. The research initiative is funded by REDDSTAR, a European Union Framework 7 (EU FP7) research collaboration focused on treating diabetes and its complications with a defined MSC therapy and enlisting academic and industry partners throughout Europe in the program (www.reddstar.eu). (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) Cardium's FDA-cleared Excellagen is an aseptically-manufactured, quaternary fibrillar Type I bovine collagen homogenate that is configured into a staggered array of three-dimensional, triple helical, telopeptide-deleted, tropocollagen molecules. This linear array forms a flowable, biocompatible and bioactive structural matrix that promotes chemotaxis, cellular adhesion, migration and proliferation to stimulate tissue formation. The Excellagen homogenate represents a new product delivery platform that allows for the potential development of a … Continue reading →

JUPITER, Fla., Aug. 6, 2013 /PRNewswire/ --BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: BRTX), a life sciences company focused on developing stem cell based cellular therapies for various personal medical applications, today announced that it has received approval from the Western Institutional Review Board ("the Board") to complete a retrospective safety study on selected subjects previously treated by the Company's brtxDISC bulging and herniated disc procedure. The study is titled "Re-consenting and Follow-Up of Adults from a Retrospective Study Using Autologous Transplantation of Marrow Derived Mesenchymal Stem Cells to Degenerated Intervertebral Disc." Study objectives are to determine the safety of subjects who received transplants of their own stem cells into their disc, using MRI and Quality of Life Questionnaires. TheBoard requires that all subjects must be able to consent for themselves to be enrolled in the study, which has been approved to take place at the Centeno-Schultz Clinic in Broomfield, Colorado. The approval allows BRT to retrospectively collect and analyze clinical data on selected subjects who previously have been treated for bulging or herniated disc disease with the Company's novel brtxDISC procedure. These procedures were performed using BRT's proprietary therapeutic delivery device cannula system and its proprietary culture … Continue reading →

August 6, 2013 April Flowers for redOrbit.com Your Universe Online A new study from the Ostrow School of Dentistry of the University of Southern California (USC) reveals stem cells found in mouth tissue can relieve inflammatory disease, as well as become other types of cells. The study, published in a recent issue of the Journal of Dental Research, focused on gingival mesenchymal stem cells (GMSC) that are found in the gingival, or gum tissue, of the mouth. Like other stem cells, GMSC have the ability to develop into different types of cells as well as affect the immune system. Gingiva is very unique in our body, says Professor Songtao Shi, associate professor at the Center for Craniofacial Molecular Biology. It has much less inflammatory reaction and heals much faster when compared to skin. Before this study, the developmental origins and abilities of GMSC had not been fully demonstrated. The USC researchers reveal there are two types of GMSC. The first type, M-GMSC, arrives from the mesoderm layer of cells during embryonic development. The second type, N-GMSC, originate from cranial neural crest cells that develop into many important structures of the head and face. N-GMSC were found to comprise 90 percent … Continue reading →

Washington, Aug 06 (ANI): Stem cells found in mouth tissue have the ability to develop into different types of cells and can also relieve inflammatory disease, a new study has revealed. The cells featured in the study by Ostrow School of Dentistry of USC were 'gingival mesenchymal' stem cells (GMSC), which are found in the gingiva, or gum tissue, within the mouth. Professor Songtao Shi, the study's senior author said that gingiva has much less inflammatory reaction and heals much faster when compared to skin. The study shows that there are two types of GMSC: those that arise from the mesoderm layer of cells during embryonic development (M-GMSC) and those that come from cranial neural crest cells (N-GMSC). The cranial neural crest cells develop into many important structures of the head and face, and 90 percent of the gingival stem cells were found to be N-GMSC. The two types of stem cells vary dramatically in their abilities. N-GMSC were not only easier to change into other types of cells, including neural and cartilage-producing cells; they also had much more of a healing effect on inflammatory disease than their counterparts. When the N-GMSC were transplanted into mice with dextrate sulfate sodium-induced … Continue reading →

COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (OSIR), the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today its results for the second quarter of 2013. Highlights and Recent Developments We are very pleased with the return our new sales team is delivering on our investments in commercial infrastructure as demonstrated by our continued revenue growth, said C. Randal Mills, Ph.D., President and Chief Executive Officer of Osiris. We are also excited about the progress of Protocol 302, our randomized, controlled clinical trial evaluating Grafix for chronic diabetic foot ulcers. By balancing our commercial and developmental activities, we continue to advance towards our goal of creating a profitable business in cell therapy by providing best-in-class products and service. Second Quarter Financial Results Product revenues during the second quarter of 2013 were $5.3 million, compared to $1.6 million during the second quarter of 2012, an increase of 231%. Gross margin during the second quarter was 72% compared to 66% during the second quarter of 2012. Gross profit was $3.8 million during the second quarter of 2013 and $1.1 million during the same period of 2012. The net … Continue reading →

Aug. 5, 2013 Stem cells found in mouth tissue can not only become other types of cells but can also relieve inflammatory disease, according to a new Ostrow School of Dentistry of USC study in the Journal of Dental Research. The cells featured in the study are gingival mesenchymal stem cells (GMSC), which are found in the gingiva, or gum tissue, within the mouth. GMSC, like other stem cells, have the ability to develop into different types of cells as well as affect the immune system. "Gingiva is very unique in our body," says Professor Songtao Shi, the study's senior author. "It has much less inflammatory reaction and heals much faster when compared to skin." Previously, the developmental origins and abilities of GMSC hadn't been fully illustrated. This study shows that there are two types of GMSC: those that arise from the mesoderm layer of cells during embryonic development (M-GMSC) and those that come from cranial neural crest cells (N-GMSC). The cranial neural crest cells develop into many important structures of the head and face, and 90 percent of the gingival stem cells were found to be N-GMSC. The two types of stem cells vary dramatically in their abilities. N-GMSC … Continue reading →

Advanced Topics - Stem Cell Therapy part 1 By: Jesse Matteson … Continue reading →

Umbilical Cord Stem Cells: Regeneration, Repair, Inflammation and Autoimmunity - Neil Riordan PhD P2 In part 2, Dr. Riordan discusses how mesenchymal stem cells can affect tissue repair in spinal cord injury and in heart failure; benefit to heart is not the ... By: http://www.cellmedicine.com … Continue reading →

Umbilical Cord Stem Cells: Regeneration, Repair, Inflammation and Autoimmunity - Neil Riordan PhD P1 (Part 1 of 2) Neil Riordan, PhD is the Founder of the Stem Cell Institute in Panama. He is also the Co-Founder of Medistem Inc in San Diego and the current P... By: http://www.cellmedicine.com … Continue reading →